Mashup Score:16
OncLiveNivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma - 2 days
Mashup Score:16
Twitter Feed: OncLive.com
Mashup Score:14
OncLiveCombination Navitoclax and Ruxolitinib Elicits Improved Bone Marrow Fibrosis in Myelofibrosis - 1 week
Mashup Score:14
Navitoclax plus ruxolitinib produced an improvement in bone marrow fibrosis and a reduction in variant allele frequency in patients with myelofibrosis who progressed on...
-
Navitoclax + ruxolitinib produced an improvement in bone marrow fibrosis and a reduction in variant allele frequency in pts w/ myelofibrosis who progressed on/ had suboptimal response with prior ruxolitinib monotherapy. @doctorpemm @MDAndersonNews #mpnsm https://t.co/i2O6nTDFpC - view on twitter
More coverage:
#mpnsm
Mashup Score:12
OncLiveIs There a Role for Biomarkers in Advanced RCC? - 7 days
Mashup Score:12
Dr Braun explains how biomarkers help to stratify treatment decision-making for patients with...
-
WATCH: @BraunMDPhD, of @YaleCancer, explains how biomarkers help to stratify treatment decision-making for patients with RCC. #kcsm #oncology https://t.co/8osdQxmlrb https://t.co/8osdQxmlrb - view on twitter
Mashup Score:10
OncLiveTrouble With the Curve: Beyond the Basics With Kaplan-Meier - 4 days
Mashup Score:10
Rahul Banerjee, MD, discusses how to navigate the obstacles in interpreting Kaplan-Meier...
-
Rahul Banerjee, MD, discusses how to navigate the obstacles in interpreting Kaplan-Meier curves. @RahulBanerjeeMD @UCSFCancer #oncology https://t.co/Bi3JRCzWnB - view on twitter
More coverage:
#oncology
Mashup Score:6
OncLiveZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma - 1 week
Mashup Score:6
The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate...
-
According to the phase 1 ZN-c3-001 trial, the investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% in patients with advanced or recurrent uterine serous carcinoma. @MDAndersonNews #gyncsm https://t.co/45ZUiaEIxB https://t.co/45ZUiaEIxB - view on twitter
More coverage:
#gyncsm
Mashup Score:5
OncLiveDr. Markowski on the Efficacy of Sabizabulin in Prostate Cancer - 4 days
Mashup Score:5
Mark C. Markowski, MD, PhD, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate...
-
WATCH: @MarkowskiGUOnc, of @hopkinskimmel, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer. #pcsm #oncology https://t.co/lfGXmWmT8a https://t.co/lfGXmWmT8a - view on twitter
Mashup Score:5
OncLiveThe FDA has granted a fast track designation to the antibody-drug conjugate CMG901 as a single-agent treatment for patients with unresectable or metastatic gastric...
-
The FDA has granted a fast track designation to the antibody-drug conjugate CMG901 as a single-agent treatment for patients with unresectable or metastatic gastric and GEJ cancer that is relapsed or refractory to approved therapies. @US_FDA #oncology https://t.co/22HUYLmux6 https://t.co/22HUYLmux6 - view on twitter
More coverage:
#oncology
Mashup Score:5
OncLiveTargeted Treatment Arsenal for Myelofibrosis Set to Explode - 1 day
Mashup Score:5
Ruben Mesa, MD, Jamile M. Shammo, MD, FASCP, FACP, Angela G. Fleischman, MD, PhD, and Stephen T. Oh, MD, PhD discuss the emerging treatment...
-
Ruben Mesa, MD, Jamile M. Shammo, MD, FASCP, FACP, Angela G. Fleischman, MD, PhD, and Stephen T. Oh, MD, PhD discuss the emerging treatment landscape in myelofibrosis. @mpdrc @MPNlab @mpndoc @UTHealthSAMDA @RushMedical @UCIrvineSOM @WUSTLmed #mpnsm https://t.co/NI732b57Qm - view on twitter
More coverage:
#mpnsm
Mashup Score:4
OncLiveAntibody-Drug Conjugates Are Carving Out Expanded Roles Throughout Breast Cancer - 2 days
Mashup Score:4
William J. Gradishar, MD, discusses the expansion of antibody-drug conjugates across subsets of breast cancer, along with emerging treatment options within each...
-
ADCs illustrate the continued evolution of treatment options across HER2+ breast cancer, HR+, HER2-negative breast cancer, and TNBC. @DrWGradishar @NUFeinbergMed #bcsm #oncology https://t.co/GJwPAS9R8Q https://t.co/GJwPAS9R8Q - view on twitter
Mashup Score:4
OncLiveIn a 16 to 0 vote, with 1 abstention, the FDA’s Oncologic Drugs Advisory Committee voted in support of basing future approvals for PI3K...
-
In a 16 to 0 vote, with 1 abstention, the FDA’s Oncologic Drugs Advisory Committee voted in support of basing future approvals for PI3K inhibitors on randomized data instead of single-arm clinical trials. @US_FDA #oncology #hematology https://t.co/tRwkgx4Aht - view on twitter
The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy...
The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve pts w/ unresectable or metastatic melanoma an efficacious & tolerable immunotherapy treatment option. @HTawbi_MD @MDAndersonNews #melsm https://t.co/3QDgudPfKA - view on twitter